Wells Fargo & Company Bio Line Rx Ltd. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Wells Fargo & Company holds 56,035 shares of BLRX stock, worth $33,621. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56,035
Previous 32,035
74.92%
Holding current value
$33,621
Previous $35,000
11.43%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding BLRX
# of Institutions
37Shares Held
4.29MCall Options Held
49.9KPut Options Held
122K-
Alyeska Investment Group, L.P. Chicago, IL1.95MShares$1.17 Million0.01% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$489,4094.05% of portfolio
-
Envestnet Asset Management Inc214KShares$128,2990.0% of portfolio
-
Values First Advisors, Inc.204KShares$122,2550.07% of portfolio
-
Pvg Asset Management Corp Golden, CO124KShares$74,1480.3% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $36.9M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...